Overview
- Leading societies issued the joint AHA/ACC/ADA/ASN guideline, published June 9–10, 2026, that formally defines CKM syndrome and establishes a four‑stage framework to guide prevention and care.
- The guidance gives a class 1 recommendation for routine risk assessment using the PREVENT equations for adults 30–79 without cardiovascular disease and explains that PREVENT incorporates kidney and metabolic measures while excluding race.
- Excess and abdominal adiposity are identified as core drivers of CKM progression and the guideline centers weight assessment and management using BMI, waist circumference, lifestyle change, GLP‑1–based therapies, SGLT2 inhibitors when indicated, and metabolic/bariatric surgery where appropriate.
- To reduce fragmented care the document endorses interdisciplinary teams, CKM coordinators or navigators, and screening for social determinants of health such as food insecurity, housing instability and financial strain.
- The guideline highlights the scale of the problem—nearly nine in ten U.S. adults have at least one CKM risk factor—and signals likely changes in clinical workflows, screening practices and use of multi‑system therapies across cardiology, nephrology and diabetes care.